Veristat Strengthens Regulatory Capabilities Across Europe and UK
Retrieved on:
Thursday, November 11, 2021
Other Science, Other Professional Services, Pharmaceutical, Research, Legal, Oncology, Medical Devices, Consulting, Infectious Diseases, Genetics, Professional Services, Stem Cells, Science, Clinical Trials, General Health, FDA, Biotechnology, Health, Medication, Compliance, Maas, Drug development, CRO, Clinical trial, DDR, RNA, United Kingdom, EMA, European Medicines Agency, Degenerative disease, Trial of the century, Multimedia, Program, Cancer, Partnership, Efficacy, Acquisition, Patient, Pharmaceutical industry, Medical device, DDR, Veristat, DDR, VERISTAT
With its proficiency in European medical regulations in particular, the acquisition builds on the proven expertise of the Veristat team responsible for regulatory insight and action at a time when significant regulatory changes are afoot.
Key Points:
- With its proficiency in European medical regulations in particular, the acquisition builds on the proven expertise of the Veristat team responsible for regulatory insight and action at a time when significant regulatory changes are afoot.
- Sponsors recognize that historical regulatory pathways are evolving, and regulatory agencies worldwide are offering greater opportunities for access and partnership.
- Architecting the ideal approach to optimize the path to a positive regulatory outcome requires collaboration with an experienced regulatory partner.
- I am pleased to welcome the exceptional DDR team to the Veristat family here in Barcelona, stated Montse Barcel Riera, M.D., Vice President, Europe for Veristat.